Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

An NHS trust in the UK has become the first site in Europe to offer Roche's experimental drug trontinemab to patients ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

At present, the only FDA-approved oral therapies for HAE are BioCryst's Orladeyo (berotralstat) and KalVista Pharma's Ekterly ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

Like LDL-cholesterol, elevated Lp (a) is recognised as an independent genetic risk factor for coronary artery disease, heart ...

Now We Must", this year emphasised the urgency and possibility of ending malaria with existing tools, progressive science, ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...